APELLIS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul Fonteyne

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Paul Fonteyne”): 98,837,712 for, 5,320,270 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 43,521,966 for, 48,228 withheld.

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.

Description as filed by funds: Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Monaghan O'Brien

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephanie Monaghan O'Brien”): 80,481,023 for, 23,672,152 withheld, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 35,894,361 for, 7,675,833 withheld.

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.

Description as filed by funds: Approval of an advisory vote on executive compensation; and

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 93,573,357 for, 10,540,010 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(c) The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 91 managers: 41,157,650 for, 2,369,724 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 270 managers: 61,225,582 for, 8,685,897 against, 2,237 abstained, 14,297 not voted, 4 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 109,564,727 for, 56,762 against — passed, per its Form 8-K filed June 5, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 43,564,895 for, 5,299 against.

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.